CoChat

The Long and Winding Road of Vagus Nerve Stimulation: Challenges in Developing an Intervention for Difficult-to-Treat Mood Disorders

Open access
Sackeim, Harold A, Dibué, Maxine, Bunker, Mark T, Rush, A John · 2020 · Neuropsychiatric Disease and Treatment

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Abstract

PURPOSE: The Vagus Nerve Stimulation (VNS) Therapy System has been studied for more than 20 years in patients with severe, treatment-resistant, chronic mood disorder, i.e., difficult-to-treat depression (DTD). This review distills some of the implications of this research for future therapeutic trials in this population. METHODS: A narrative review is provided on VNS in DTD. Protocols for a new, large, sham-controlled trial and a global, longitudinal observational study are described. RESULTS: Following encouraging results in open studies, a randomized, masked, sham-controlled trial of VNS for DTD failed to demonstrate an effect on the primary outcome. The negative results may have been partly due to inadequate treatment duration (10 weeks). In long-term observational studies, adjunctive VNS, combined with treatment-as-usual (VNS+TAU), was administered to more than 1100 DTD patients and compared with TAU alone in more than 400 patients. VNS+TAU had superior antidepressant effects, but maximal symptom reduction was often observed after 12 months or longer of stimulation. VNS+TAU had also marked superiority in durability of benefit. Sustained levels of symptom reduction below the traditional cutoff for response (i.e. < 50%) were associated with improved quality of life. LIMITATIONS: Most comparisons of VNS+TAU and TAU were derived from observational, open label studies. CONCLUSION: The history of VNS in DTD has implications for interventional studies in this population, and perhaps other chronic medical disorders. The slow onset of benefit with VNS necessitates considerably longer controlled observation periods to establish efficacy. Durability of benefit should be routinely incorporated in efficacy assessment. New outcome metrics are needed to both categorically identify clinically meaningful benefit and to integrate information on symptom burden over time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s286977

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. 2017, Guiding Principles for Developing Dietary Reference Intakes Based on Chronic Disease
  2. Sackeim, 1983, Biol Psychiatry, 18, 1301
  3. Dunn, 1998, Clin Neuropharmacol, 21, 215
  4. Sackeim, 2001, J Clin Psychiatry, 62, 10
  5. Depression Guideline Panel. Depression in primary care: Vol.2. Treatment of major depression. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR. No. 93-0551; 1993.
  6. Nobler, 1997, Convuls Ther, 13, 208

Cited by

See all 15

Metadata

Authors
Sackeim, H. A., Dibué, M., Bunker, M. T., & Rush, A. J.
Affiliations
  • Heinrich Heine University Düsseldorf (DE)
  • LivaNova (United States) (US)
  • Texas Tech University (US)
Venue
Neuropsychiatric Disease and Treatment
Published
2020-12
Volume
Volume 16
Pages
3081-3093
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
OpenAlex
W3111892362
Cited by
15
References
95
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 2
FWCI
0.20
Type
journal article
Language
en
Open access
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
LivaNova
Topics
  • Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
vagus nerve stimulation, treatment-resistant depression, mood disorders, adjunctive therapy, treatment duration, quality of life, outcome measures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.